Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK announces Dr Vishal Sikka to join the Board as Non-Executive Director
GSK has announced that Dr Vishal Sikka, founder and CEO of Vianai Systems, will join the Board of the Company as a Non-Executive Director.
Read more -
SK bioscience and GSK’s adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea
SK submits license application to MFDS to support vaccine sovereignty in South Korea
Read more -
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER, +32% CER; Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER, +43% CER
Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand
Read more -
US Food and Drug Administration accepts New Drug Application for daprodustat
US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat
Read more -
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
Myelofibrosis is a fatal cancer of the bone marrow impacting the normal production of blood cells.
Read more -
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
According to UNAIDS, approximately 1.7 million children globally were living with HIV in 2020.
Read more -
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period
US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment.
Read more -
GSK to demonstrate its commitment to improving outcomes for patients with gynaecologic cancer at the 2022 SGO Annual Meeting
The meeting will take place in Phoenix, Arizona, and virtually from 18-21 March 2022
Read more -
GSK announces appointments to Designate Haleon Board
GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the appointment of six directors to the designate Board of Haleon.
Read more -
European Medicines Agency (EMA) accepts marketing authorisation application for daprodustat
The EMA has validated the MAA for daprodustat, for the treatment of patients with anaemia of chronic kidney disease.
Read more -
GSK introduces Haleon to investors
Global leader in consumer health set to be a newly independent company
Read more -
GSK provides further update on phase III RSV maternal vaccine candidate programme
Further to the voluntary pause shared on February 18, the Company has decided to stop enrolment and vaccination in trials
Read more -
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
A vaccine manufactured in plants and developed in Canada
Read more -
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Sanofi and GSK today announce that they intend to submit data from both their booster and Phase 3 efficacy trials
Read more -
GSK announces independent Consumer Healthcare company is to be called Haleon
Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands.
Read more -
GSK provides update on phase III RSV maternal vaccine candidate programme
GSK gives update on RSV maternal vaccine candidate
Read more -
China’s National Medical Products Administration approves Benlysta (belimumab) for adult patients with active lupus nephritis
First and only biologic approved in China for both systemic lupus erythematosus and lupus nephritis
Read more -
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER; Total EPS 87.6p -24% AER, -13% CER and Adjusted EPS of 113.2p -2% AER, +9% CER
GSK delivers FY 2021 reported sales of £34 billion, stable at AER, +5% CER.
Read more -
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022
ViiV Healthcare to present new long-term findings at CROI 2022
Read more -
GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement
Gilead will make an upfront payment of $1.25 billion to ViiV Healthcare in the first quarter of 2022
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
